GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Scholar Rock
Shares of Scholar Rock, a biotech company focused on treating muscle diseases, are driven by the progress of clinical trials. The stock price reflects investor hopes for a breakthrough in the treatment of conditions like spinal muscular atrophy.
Share prices of companies in the market segment - Pharma neurology
Scholar Rock is a biotech company focused on treating muscle diseases. We classify it as a pharmaceutical (neurology) company, and the chart below reflects general trends and investor sentiment in this biotech sector.
Broad Market Index - GURU.Markets
Scholar Rock is a biopharmaceutical company developing drugs to treat diseases associated with muscle atrophy and fibrosis. As a component of the GURU.Markets index, it represents the biotech sector. The chart below represents the entire market. See how Scholar Rock shares compare to the overall trend.
Change in the price of a company, segment, and market as a whole per day
SRRK - Daily change in the company's share price Scholar Rock
For Scholar Rock, a biopharmaceutical company, change_co is a measure of the sector's inherently high volatility. Each daily change reflects its sensitivity to news about clinical trials of its drugs. This metric isn't just noise, but a critical component of the models at System.GURU.Markets that assess risk in innovative medicine.
Daily change in the price of a set of shares in a market segment - Pharma neurology
Scholar Rock Holding Corporation is a biotech company. This chart highlights the sector's extreme volatility. Comparison with SRRK, which focuses on rare disease treatments, helps to assess it as a high-risk, clinical-data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Scholar Rock is a biopharmaceutical company developing drugs to treat diseases of the muscle and nervous system. Neuroscience is a risky field of research. The chart below illustrates the high volatility typical of the biotech sector, reflecting the stakes associated with Scholar Rock's developments.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Scholar Rock
Scholar Rock is a biotech company working on treatments for neurological diseases. Its shares represent a venture capital bet on scientific success. Their high volatility, driven by expectations, contributes to the complex and multifaceted dynamics of the entire stock market.
Annual dynamics of market capitalization of the market segment - Pharma neurology
Scholar Rock Holding Corporation is a biotech company developing a new class of drugs for the treatment of muscular diseases. Its stock performance is entirely dependent on clinical trial results. The chart reflects the high risks and potential for breakthroughs typical of the biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Scholar Rock is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the key events are data releases, not macroeconomic statistics.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Scholar Rock
Scholar Rock, a biotech company specializing in treating muscle-related diseases, has sharp monthly fluctuations reflecting the release of clinical trial data from its drugs, a key factor for companies at this stage.
Monthly dynamics of market capitalization of the market segment - Pharma neurology
Scholar Rock is a biopharmaceutical company developing a new class of drugs targeting growth factors for the treatment of neuromuscular and other serious diseases. The dynamics of its sector, shown in the chart, reflect the high risks and potential of biotech. Against this backdrop, it's possible to assess how scientific data and clinical trial progress influence investor perceptions of this innovative company.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Scholar Rock is a biopharmaceutical company focused on treating muscle diseases. Biotech stocks often move independently of the market, reacting to clinical trial data. The chart below shows how much news from the Scholar Rock laboratory allowed its stock to buck the overall market trend.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Scholar Rock
Shares of Scholar Rock, a biopharmaceutical company, move in sync with clinical trial news. Weekly price movements reflect investor expectations for breakthrough treatments for neuromuscular diseases. The chart below illustrates how any news about clinical trials can trigger sharp short-term price fluctuations.
Weekly dynamics of market capitalization of the market segment - Pharma neurology
How unique is Scholar Rock's performance in the biotech sector? This chart compares the company's weekly stock price movements, driven by clinical trial news, with the overall sector trend. This helps us understand whether a sharp stock move is the result of a unique scientific breakthrough or a reflection of overall investor sentiment in this volatile industry.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Scholar Rock is a biotech company whose shares thrive on clinical trial news. This chart clearly demonstrates how its weekly performance can completely defy overall market trends. A sharp rise or fall can be triggered by data releases while the overall market remains stagnant.
Market capitalization of the company, segment and market as a whole
SRRK - Market capitalization of the company Scholar Rock
Scholar Rock's valuation on the chart reflects investor hopes for its innovative approach to treating muscle diseases. As a biotech company, its market cap is heavily dependent on clinical trial success. Its share price movement reflects how the market reacts to each news item about a potential medical breakthrough.
SRRK - Share of the company's market capitalization Scholar Rock within the market segment - Pharma neurology
Scholar Rock is a biotech company developing drugs to treat serious diseases by targeting growth factors. Its share of its sector market capitalization reflects the potential of its scientific platform. The chart shows how investor expectations for clinical trials and potential treatment breakthroughs shape its market value and industry weight.
Market capitalization of the market segment - Pharma neurology
This chart illustrates the total market capitalization of the biotech segment targeting rare neurological diseases. Scholar Rock is an innovator in this complex field. The dynamics on the chart reflect the overall hopes and risks of investors investing in life-changing science.
Market capitalization of all companies included in a broad market index - GURU.Markets
This chart shows the market value of a potential breakthrough in the treatment of muscle diseases. Scholar Rock's market cap is not based on current sales, but rather on investors' faith in the company's scientific platform. The line shows how a single biotech idea can grow into a significant player in the global pharmaceutical market.
Book value capitalization of the company, segment and market as a whole
SRRK - Book value capitalization of the company Scholar Rock
The book value of Scholar Rock, a biotech company, is its research capital. The chart below reflects the value of its research equipment and, more importantly, its intellectual property—patents for drugs treating neuromuscular diseases. A rising line indicates success in research and development.
SRRK - Share of the company's book capitalization Scholar Rock within the market segment - Pharma neurology
For biotech company Scholar Rock, physical assets aren't production lines, but cutting-edge laboratories and specialized equipment for developing complex drugs. The chart shows the company's control over the company's valuable scientific infrastructure in its niche, demonstrating its research potential.
Market segment balance sheet capitalization - Pharma neurology
Scholar Rock is a clinical-stage biotech company. Its value is created not in factories, but in the labs where innovative drugs are developed. This is a "lightweight" model based on intellectual capital. The chart below illustrates the extent to which the biopharmaceutical industry as a whole relies on tangible assets.
Book value of all companies included in the broad market index - GURU.Markets
Scholar Rock's balance sheet isn't made up of machines and factories, but rather capital invested in cutting-edge scientific research and patents in the treatment of muscle diseases. The book value chart shows the extent of financial resources concentrated in this breakthrough area of biotechnology.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Scholar Rock
Scholar Rock is a research-stage biotech company. Its book value is cash in the bank. Its market capitalization represents investors' pure expectations and hopes for a breakthrough in the treatment of muscle diseases using its innovative molecules. The chart clearly demonstrates how a scientific hypothesis and the potential of a future drug generate multi-million dollar value.
Market to book capitalization ratio in a market segment - Pharma neurology
Scholar Rock is a biopharmaceutical company focused on treating muscle diseases. Its value comes from its research and patents, not its labs. This metric clearly demonstrates how market capitalization, based on hopes for future drugs, far exceeds the value of its tangible assets.
Market to book capitalization ratio for the market as a whole
Scholar Rock is a biotech company focused on treating muscular diseases. The chart illustrates the classic biotech story: market valuation is based on hope. Investors value the company's scientific developments, not its current assets, but the potential for a successful drug. Therefore, the market value can be tens of times higher than the book value, reflecting the premium for innovation.
Debts of the company, segment and market as a whole
SRRK - Company debts Scholar Rock
Scholar Rock is a biotech company focused on treating diseases by targeting growth factors. Funding lengthy and expensive clinical trials is a key challenge. This chart shows how the company raises capital, including debt, to advance its research and development to the commercialization stage.
Market segment debts - Pharma neurology
Scholar Rock is a biotech company developing drugs to treat serious diseases by targeting growth factors. Funding in this sector often comes from venture capital and partnerships, rather than traditional debt. This chart shows common financial metrics for the pharmaceutical industry, highlighting the specific characteristics of companies in the R&D stage.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Scholar Rock
Scholar Rock is a biotech company developing drugs to treat serious diseases by targeting protein growth factors. Funding multi-year clinical trials requires significant resources. This chart shows the proportion of the company's capital structure that is comprised of debt to advance its developments toward commercialization.
Market segment debt to market segment book capitalization - Pharma neurology
Scholar Rock is a biotech company focused on treating neuromuscular diseases, which require lengthy and expensive clinical trials. This chart compares its debt raised to fund research to the overall market capitalization of the pharmaceutical sector. It demonstrates the scale of its scientific ambitions and financial risks.
Debt to book value of all companies in the market
Scholar Rock is a biotech company whose debt finances cutting-edge research. This chart plots its debt against the overall market capitalization of the economy. It shows how ambitious the company's scientific ambitions are and how its capital needs compare to the overall health of the stock market, its source of funding.
P/E of the company, segment and market as a whole
P/E - Scholar Rock
This chart shows the valuation of Scholar Rock, a biotech focused on treating neuromuscular diseases. For a clinical-stage company with no stable revenue streams, its value is determined by the potential of its scientific developments. The chart reflects investors' faith in the future commercial success of its drugs, not its current financial performance.
P/E of the market segment - Pharma neurology
This metric represents the average valuation for the biotech sector in which Scholar Rock operates. In this industry, filled with research-stage companies, the average earnings valuation is often uninformative. However, it does reflect the overall level of investor optimism regarding scientific breakthroughs and serves as a benchmark for understanding a company's value.
P/E of the market as a whole
Scholar Rock is a biotech company developing drugs to treat serious diseases by targeting muscle and bone growth factors. It's a risky but potentially highly profitable business. This chart provides insight into the overall market sentiment toward biotech innovation and the market's risk appetite.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Scholar Rock
Scholar Rock is a biotech company developing drugs to treat serious diseases by targeting protein growth factors. This chart reflects market expectations regarding the success of clinical trials and the future commercial potential of its developments. It estimates the likelihood of a scientific breakthrough that will generate future profits for the company.
%20P%2FE%20Scholar%20Rock&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Scholar-Rock&v=1772513720844 "Chart of the company's future (projected) P/E Scholar Rock")
Future (projected) P/E of the market segment - Pharma neurology
Scholar Rock is a biopharmaceutical company focused on developing innovative drugs to treat serious diseases involving growth factors, such as muscle and neurological disorders. This chart shows overall market sentiment toward the biotech sector, helping to assess Scholar Rock's potential relative to industry expectations.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-neurology&v=1772513720904 "Future (projected) P/E graph of the market segment - Pharma neurology")
Future (projected) P/E of the market as a whole
Scholar Rock is a biotech company developing drugs to treat diseases associated with muscle atrophy and fibrosis. Its valuation is based on the expectation of success in clinical trials. Compared to general market forecasts, Scholar Rock is a story about science, where research data trumps macroeconomic trends.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513720962 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Scholar Rock
Scholar Rock is a biotech company specializing in the treatment of growth factor-related diseases, particularly muscle disorders. Because the company is in the research stage, its financial metrics primarily reflect R&D expenses. This chart shows periods of heavy investment in clinical trials, which are key to future profits.
Profit of companies in the market segment - Pharma neurology
Scholar Rock is a biopharmaceutical company developing drugs to treat muscle-related diseases, such as spinal muscular atrophy. This chart shows the overall profitability of the neuroscience pharmaceutical sector. While in the research stage, the company impacts overall profitability through its R&D investments, and its successes could radically change the future of the entire segment.
Overall market profit
Scholar Rock is a biotech company focused on treating serious diseases by targeting growth factors. Its market capitalization depends on clinical trial results, not the state of the economy. This graph of total corporate returns illustrates how innovative companies like Scholar Rock can create value independently of broader market trends.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Scholar Rock
Scholar Rock is a biotech company focused on treating serious growth factor-related diseases, such as muscle wasting disease. This chart shows analysts' future earnings expectations based on the potential of its drug candidates. Sharp forecast changes are often driven by clinical trial results, which determine the company's future.
%20profit%20of%20the%20company%20Scholar%20Rock&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Scholar-Rock&v=1772513721228 "Graph of future (projected) profit of the company Scholar Rock")
Future (predicted) profit of companies in the market segment - Pharma neurology
Scholar Rock is a biotech company developing drugs to treat serious diseases by targeting protein growth factors. This chart shows profitability expectations for the neuroscience segment of the pharmaceutical industry. It reflects investor optimism regarding the breakthrough treatments that Scholar Rock is pursuing.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-neurology&v=1772513721244 "Graph of future (predicted) profits of companies in a market segment - Pharma neurology")
Future (predicted) profit of the market as a whole
Scholar Rock is a biotech company developing drugs to treat serious diseases by targeting growth factors. Innovative pharmaceuticals require significant investment. The overall profit forecast shown here influences investors' risk appetite. Positive market dynamics make it easier for Scholar Rock to raise capital for its expensive clinical trials.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513721337 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Scholar Rock
Scholar Rock is a biotech company developing drugs to treat serious diseases. Revenue can be minimal during the research and development phase. The P/S ratio becomes significant once the company begins commercialization. The chart shows how the market values initial sales, factoring in the potential of the entire scientific platform.
P/S market segment - Pharma neurology
Scholar Rock is a biopharmaceutical company focused on treating growth factor-related diseases, particularly neuromuscular disorders. Being in the clinical stage, its valuation is based on future revenue potential. This chart shows how much confidence the market has in their scientific approach compared to other biotech companies.
P/S of the market as a whole
Scholar Rock is a biotech company developing drugs to treat neuromuscular disorders. Its current revenue is minimal or nonexistent, and its market cap reflects expectations for future success. This chart shows how the market values actual revenue, highlighting the speculative nature of early-stage biotech valuations.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Scholar Rock
Scholar Rock is a biopharmaceutical company developing drugs to treat growth factor-related diseases. Its valuation is based almost entirely on the prospects of its pipeline. This chart shows how the market values the potential future commercial success of its drug candidates, pricing them in to reflect their likelihood of reaching market.
%20P%2FS%20Scholar%20Rock&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Scholar-Rock&v=1772513721668 "The graph of the company's future (projected) P/S Scholar Rock")
Future (projected) P/S of the market segment - Pharma neurology
Scholar Rock is a biotech company developing innovative drugs to treat growth factor-related diseases, including muscle disorders. This chart shows how the market assesses the future commercial potential of its developments compared to other pharmaceutical companies, reflecting confidence in its scientific approach and clinical development prospects.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-neurology&v=1772513721802 "Future (projected) P/S market segment graph - Pharma neurology")
Future (projected) P/S of the market as a whole
Scholar Rock is a biotech company developing drugs to treat muscular diseases. Its success depends on the results of clinical trials and the ability to bring innovative drugs to market. This chart shows revenue expectations for the entire market, allowing us to assess investors' risk appetite and their belief in future medical breakthroughs.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513721845 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Scholar Rock
Scholar Rock is a clinical-stage biopharmaceutical company specializing in the treatment of growth factor-associated diseases, particularly muscle disorders. This chart reflects revenues generated not from sales but from licensing agreements and collaborations. Revenue growth will depend on successful clinical trials and drug commercialization.
Sales of companies in the market segment - Pharma neurology
Scholar Rock is a biotech company developing drugs to treat neuromuscular disorders. This chart shows the company's revenue structure, which currently consists primarily of payments from major pharmaceutical partners. This allows one to assess the industry's confidence in its developments and its financial stability.
Overall market sales
Scholar Rock is a biopharmaceutical company focused on treating serious diseases by targeting growth factors. Its value and revenue potential depend on the success of clinical trials, not macroeconomic trends. This overall market performance graph does not reflect scientific progress, which is Scholar Rock's sole driver.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Scholar Rock
The revenue forecast for Scholar Rock, a biopharmaceutical company focused on treating muscle diseases such as muscular atrophy, is critically important. It reflects analysts' expectations regarding the success of clinical trials and the future commercial potential of its innovative drugs aimed at breaking through in the treatment of rare diseases.
%20sales%20of%20the%20company%20Scholar%20Rock&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Scholar-Rock&v=1772513721956 "Schedule of future (projected) sales of the company Scholar Rock")
Future (projected) sales of companies in the market segment - Pharma neurology
Scholar Rock is a biotech company developing drugs to treat neuromuscular disorders. This chart shows projected revenues for the entire neuroscience pharmaceutical segment. It allows investors to assess whether analysts see growth potential in this complex area, which is critical for the future commercial prospects of Scholar Rock's innovative drugs.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-neurology&v=1772513721976 "Schedule of future (projected) sales of companies in the market segment - Pharma neurology")
Future (projected) sales of the market as a whole
Scholar Rock is a biotech company developing drugs to treat growth factor-related diseases, such as muscle wasting. While demand for its future products isn't dependent on the economy, investor sentiment is. This chart reflects overall market confidence, which impacts the availability of capital for Scholar Rock's long-term and risky R&D projects.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513722027 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Scholar Rock
Scholar Rock is a biotech company focused on treating serious diseases by targeting growth factors. This chart reflects the intensive research stage. It doesn't show profit, but rather the effectiveness of capital management invested in drug development, the success of which determines the company's future profitability.
Market segment marginality - Pharma neurology
Scholar Rock is a biotech company developing drugs to treat serious diseases by targeting growth factors. This chart helps assess its potential commercial success. If its future profitability exceeds industry benchmarks, it will confirm the breakthrough nature of its scientific research.
Market marginality as a whole
Scholar Rock is a clinical-stage biotech company developing drugs to treat serious diseases by targeting growth factors. Its value is determined not by current revenue, but by the potential of future drugs. This graph of average market returns shows the present, while Scholar Rock investors are betting on the distant future.
Employees in the company, segment and market as a whole
Number of employees in the company Scholar Rock
Scholar Rock is a biotech company developing drugs for the treatment of neuromuscular diseases. Its team is primarily comprised of scientists and clinical trial specialists. Increases in staff, as seen on the graph, often indicate progress in the development of key drugs and the transition to later, larger-scale trials.
Share of the company's employees Scholar Rock within the market segment - Pharma neurology
Scholar Rock is a biopharmaceutical company developing innovative drugs to treat serious diseases by targeting growth factors. This chart reflects its scientific strength. It shows the proportion of highly qualified biologists and chemists working in the cutting-edge field of growth factor modulation that Scholar Rock brings together to create the next generation of drugs.
Number of employees in the market segment - Pharma neurology
Scholar Rock develops drugs to treat serious diseases by targeting growth factors. This chart illustrates the talent pool in neurological pharmaceuticals. The growing number of scientists and specialists in this field indicates an influx of investment in complex brain and nervous system research, paving the way for innovation and success at Scholar Rock.
Number of employees in the market as a whole
Scholar Rock is a biopharmaceutical company focused on treating spinal muscular atrophy. The growth of its scientific and clinical staff is an indicator of progress in the development of innovative drugs. This is an investment in a high-tech sector where job creation is directly linked to saving lives, not market conditions.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Scholar Rock (SRRK)
Scholar Rock is a clinical-stage biotech developing drugs to treat muscle diseases. Their current market cap is not based on revenue, but on investor expectations for future drugs. This chart shows how the market values their scientific potential. The billion-dollar market cap, attributed to a small staff of scientists, is a measure of their intellectual capital.
%20of%20the%20company%20Scholar%20Rock%20(SRRK)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Scholar-Rock-SRRK&v=1772513722195 "Chart of market capitalization per employee (in thousands of dollars) of the company Scholar Rock (SRRK)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma neurology
Scholar Rock is a biotech company developing drugs to treat serious diseases, such as spinal muscular atrophy. Being in the clinical stage, its value lies in its research and patents. This chart shows the industry average. It helps assess the premium the market places on each of the company's scientists and researchers.
%20by%20market%20segment%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-neurology&v=1772513722278 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma neurology")
Market capitalization per employee (in thousands of dollars) for the overall market
Scholar Rock is a biotech company developing drugs to treat diseases associated with muscle wasting. Its value is concentrated in the team's scientific potential. This chart reflects investors' expectations for future clinical success: a high valuation per employee indicates confidence in their ability to create a breakthrough drug.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513722356 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Scholar Rock (SRRK)
Scholar Rock is a clinical-stage biotech company specializing in drugs for muscle disorders. Their business is science and clinical trials. They have no profit yet, only R&D expenses. This chart shows the amount of investment burned per scientist and employee working on future breakthrough drugs.
%20Chart%20Scholar%20Rock%20(SRRK)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Scholar-Rock-SRRK&v=1772513722445 "Company Profit Per Employee (in thousands of dollars) Chart Scholar Rock (SRRK)")
Profit per employee (in thousands of dollars) in the market segment - Pharma neurology
Scholar Rock is a clinical-stage biotech company specializing in treating severe diseases (muscle atrophy). This chart shows the benchmark for the "Biotech" sector. In this sector, the benchmark for profit per employee is typically *deeply negative*. Companies "burn" money on R&D (clinical trials) in anticipation of a future breakthrough.
%20in%20the%20market%20segment%20-%20Pharma%20neurology&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-neurology&v=1772513722555 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma neurology")
Profit per employee (in thousands of dollars) for the market as a whole
Scholar Rock is a biotech company specializing in treating diseases associated with muscle wasting. It's a deeply scientific R&D company. This chart, showing the average dollar return per employee across the market, asks the question: how does the biotech sector, where a single scientist can create billions of dollars in value, compare to average profitability?
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513722577 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Scholar Rock (SRRK)
Scholar Rock, a biotech company, is in the research stage, and its revenue per employee doesn't reflect current operating activity. Rather, the graph demonstrates investors' confidence in the future success of its drugs. If the product is commercialized, this figure will skyrocket, demonstrating a huge return on the intellectual capital invested.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Scholar-Rock-SRRK&v=1772513722606 "Sales chart per company employee Scholar Rock (SRRK)")
Sales per employee in the market segment - Pharma neurology
Scholar Rock is a biotech company developing drugs to treat muscular and neurological diseases. Revenue is often absent during the R&D phase. This chart shows the average revenue per employee in this segment, setting a productivity benchmark for commercial companies. It helps assess how effective Scholar Rock's staff is in the context of the industry as a whole.
Sales per employee for the market as a whole
Scholar Rock is a clinical-stage biotech company specializing in the treatment of muscle diseases. Like Crinetics, this metric doesn't yet reflect business performance, as revenue is almost nonexistent. Instead, it reflects the "cost" of research. Investors watch this chart for a sharp increase that would signal drug approval and the start of sales.
Short shares by company, segment and market as a whole
Shares shorted by company Scholar Rock (SRRK)
Scholar Rock is a biotech company focused on treating rare diseases, particularly muscle wasting, by targeting specific proteins. This chart reflects high skepticism. The "short sellers" here are a classic anti-biotech bet: they expect the clinical trials, which are the sole driver of the company's value, to fail.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Scholar-Rock-SRRK&v=1772513722742 "Short Shares Chart for the Company Scholar Rock (SRRK)")
Shares shorted by market segment - Pharma neurology
Scholar Rock is a clinical-stage biotech developing drugs for neuromuscular disorders. Success for such companies is binary. This chart shows the pessimism across the biotech sector. The rise in short positions across the industry means investors have become generally risk-averse, making it difficult to raise capital and negatively impacting the valuations of all small pharma companies.
Shares shorted by the overall market
Scholar Rock (SRRK) is a clinical-stage biotech developing drugs to treat neuromuscular diseases. The success of such companies depends on scientific breakthroughs, not economics. However, this chart reflects general market fear. When fear is high, investors flee speculative biotechs in need of funding, which hurts SRRK shares regardless of their performance.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Scholar Rock (SRRK)
Scholar Rock is a clinical-stage biotech. Its shares are highly sensitive to trial news. This chart for SRRK can surge above 70 on positive R&D data. Oversold territory (<30) often reflects research setbacks or general investor risk aversion in biotech.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Scholar-Rock-SRRK&v=1772513722860 "RSI 14 indicator chart for the company's stock Scholar Rock (SRRK)")
RSI 14 Market Segment - Pharma neurology
Scholar Rock is a biotech company focused on treating rare diseases, specifically muscular atrophy (SMA). They are developing drugs that target muscle growth. This chart shows the overall momentum in the rare disease biotech sector. It helps assess whether the entire segment is overheated by expectations.
RSI 14 for the overall market
Scholar Rock (SRRK) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast SRRK (Scholar Rock)
Scholar Rock is a biotech company focused on treating diseases associated with muscle wasting. The company's future depends on clinical trials. This chart shows analyst consensus forecasts. Their targets reflect the estimated likelihood of success for key drugs in development and the potential market size for these innovative treatments.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-SRRK-Scholar-Rock&v=1772513723077 "A chart showing analyst consensus forecasts for the expected stock price. SRRK (Scholar Rock)")
The difference between the consensus estimate and the actual stock price SRRK (Scholar Rock)
Scholar Rock is a clinical-stage biotech developing drugs to treat severe muscle diseases such as spinal muscular atrophy (SMA). They target the protein myostatin to promote muscle growth. This chart reflects analyst expectations for their clinical trials. It shows the gap between the target price and the current price.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-SRRK-Scholar-Rock&v=1772513723119 "A chart showing the difference between the consensus forecast and the actual stock price. SRRK (Scholar Rock)")
Analyst consensus forecast for stock prices by market segment - Pharma neurology
Scholar Rock is a biotech company attacking diseases (like SMA) from a unique angle: it develops drugs that *grow* muscle mass. This chart shows analysts' overall expectations for the entire neuroscience/biotech sector. It reflects whether experts believe this innovative, but risky, therapy will be a breakthrough.
Analysts' consensus forecast for the overall market share price
Scholar Rock (SRRK) is a biotech company focused on treating muscle-wasting diseases (such as SMA). They are developing drugs that aim to stimulate muscle growth. This chart shows the overall risk appetite in the market, reflecting the willingness of investors to fund breakthrough but high-risk scientific research.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Scholar Rock
Scholar Rock is a biotech company working on breakthrough treatments for rare diseases, particularly muscle diseases (SMA). They are developing drugs aimed at unlocking muscle growth. This chart represents pure R&D betting. It likely reflects investors' faith in successful clinical trials and the scientific potential of their platform, rather than revenue.
AKIMA Market Segment Index - Pharma neurology
Scholar Rock (SRRK) is a clinical-stage biotech and a pioneer in the treatment of muscle diseases. The company is developing myostatin-blocking drugs (Apitegromab) for the treatment of SMA (spinal muscular atrophy). This summary metric evaluates R&D. The graph shows the average value for the segment. This benchmark: how does SRRK's breakthrough (SMA) R&D platform differentiate it from the average pharma company?
The AKIM Index for the overall market
Scholar Rock is a biotech company focused on rare muscle diseases. It's a high-risk scientific bet on a future cure. This chart, which reflects the market average, is an indicator of risk appetite. It reveals the macro backdrop, which is critical for funding companies like Scholar Rock.
